I think there is probably quite a large pocket of retail investors who love biotech and lap up any media produced in the sector and of particular interest is hearing from a specialist biotech investor which is relatively rare in Aus - for whatever reason, presumably to drum up interest in his new fund, Hashan has been on a fair media go around in the last few months.
But I agree with you - whilst the Neuren trade is impressive, he wasn't the only one, and it doesn't mean everything he is involved in will turn to gold.
Add to My Watchlist
What is My Watchlist?
